Oliver Brunckhorst1, Safiya Hashemi2, Anastasia Martin2, Gincy George3, Mieke Van Hemelrijck3, Prokar Dasgupta2, Robert Stewart4,5, Kamran Ahmed2,6. 1. MRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, UK. oliver.brunckhorst@kcl.ac.uk. 2. MRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, UK. 3. Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. 4. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. 5. South London and Maudsley NHS Foundation Trust, London, UK. 6. Department of Urology, King's College Hospital, London, UK.
Abstract
BACKGROUND: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. METHODS: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. RESULTS: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36-7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14-19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92-18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31-12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85-54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. CONCLUSIONS: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.
BACKGROUND: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. METHODS: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. RESULTS: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36-7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14-19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92-18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31-12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85-54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. CONCLUSIONS: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.
Authors: Zachary Klaassen; Christopher J D Wallis; Thenappan Chandrasekar; Hanan Goldberg; Rashid K Sayyid; Stephen B Williams; Kelvin A Moses; Martha K Terris; Robert K Nam; David Urbach; Peter C Austin; Paul Kurdyak; Girish S Kulkarni Journal: Cancer Date: 2019-04-25 Impact factor: 6.860
Authors: Cristiano Scandurra; Francesco Mangiapia; Roberto La Rocca; Francesco Di Bello; Natascia De Lucia; Benedetta Muzii; Micaela Cantone; Rita Zampi; Gianluigi Califano; Nelson Mauro Maldonato; Nicola Longo Journal: Support Care Cancer Date: 2022-05-18 Impact factor: 3.359
Authors: Michael Heinrich; Luisa Hofmann; Hansjörg Baurecht; Peter M Kreuzer; Helge Knüttel; Michael F Leitzmann; Corinna Seliger Journal: Nat Med Date: 2022-03-28 Impact factor: 87.241
Authors: Cristiano Scandurra; Benedetta Muzii; Roberto La Rocca; Francesco Di Bello; Mario Bottone; Gianluigi Califano; Nicola Longo; Nelson Mauro Maldonato; Francesco Mangiapia Journal: Int J Environ Res Public Health Date: 2022-04-15 Impact factor: 4.614
Authors: Kate Oppegaard; Carolyn S Harris; Joosun Shin; Steven M Paul; Bruce A Cooper; Jon D Levine; Yvette P Conley; Marilyn Hammer; Frances Cartwright; Fay Wright; Laura Dunn; Kord M Kober; Christine Miaskowski Journal: Support Care Cancer Date: 2021-06-26 Impact factor: 3.603
Authors: Omar Eymech; Oliver Brunckhorst; Louis Fox; Anam Jawaid; Mieke Van Hemelrijck; Robert Stewart; Prokar Dasgupta; Kamran Ahmed Journal: Support Care Cancer Date: 2022-03-19 Impact factor: 3.359
Authors: Simon M Rice; David Kealy; John S Ogrodniczuk; Zac E Seidler; Gabriela Montaner; Suzanne Chambers; John L Oliffe Journal: Am J Mens Health Date: 2021 May-Jun
Authors: Guendalina Gentile; Stefano Tambuzzi; Raffaella Calati; Riccardo Zoja Journal: Int J Environ Res Public Health Date: 2022-01-12 Impact factor: 3.390
Authors: Katja Leuteritz; Diana Richter; Anja Mehnert-Theuerkauf; Jens-Uwe Stolzenburg; Andreas Hinz Journal: Qual Life Res Date: 2021-07-18 Impact factor: 4.147